

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 17, 2003 (use as many sheets as necessary)				Complete if Known	
				Application Number	Unassigned
				Filing Date	11/17/03
				First Named Inventor	S. V. Govindan
				Group Art Unit	Unassigned 1639
				Examiner Name	Unassigned celSA
Sheet	1	of	2	Attorney Docket Number	018733-1317

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
<i>ML</i>	A1	5,274,076	530	Barbet <i>et al.</i>	12-28-1993	
<i>ML</i>	A2	5,273,738	424	Matthews <i>et al.</i>	12-28-1993	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
<i>ML</i>	A3	EP	0 419 387			03-27-1991		
<i>ML</i>	A4	EP	0 492 478			07-01-1992		
<i>ML</i>	A5	GB	2 109 407			06-02-1983		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>ML</i>	A6	Goldenberg, D. M., "Monoclonal Antibodies in Cancer Detection and Therapy," <i>The American Journal of Medicine</i> , (March 1993) 94:297-312.	
<i>ML</i>	A7	Strobel, J. L. <i>et al.</i> , "I-Glycoconjugate Labels for Identifying Sites of Protein Catabolism <i>in Vivo</i> : Effect of Structure and chemistry of Coupling to Protein on Label Entrapment in Cells after Protein Degradation," <i>Archives of Biochemistry and Biophysics</i> , (August 1985) 240(2):635-645.	
<i>ML</i>	A8	Franano, F. N. <i>et al.</i> , "Metabolism of Receptor Targeted ¹²⁵ I-DTPA-Glycoproteins: Identification of ¹²⁵ I-DTPA- α -lysine as the Primary Metabolic and Excretory Product," <i>Nucl Med. Biol</i> (1994) 21(8):1023-1034.	
<i>ML</i>	A9	Dumas, P. <i>et al.</i> , "Spécificité de L'iodotyrosine Desiodase des Microsomes Thyroïdiens et Hépatiques," <i>Biochimica et Biophysica Acta</i> (1973) 293:36-47.	

Examiner Signature		Date Considered	3/3/05
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 17, 2003 (use as many sheets as necessary)		Application Number	Unassigned
		Filing Date	11/17/03
		First Named Inventor	S. V. Govindan
		Group Art Unit	Unassigned <i>Div 3-9</i>
		Examiner Name	Unassigned <i>Celsa</i>
Sheet 2 of 2	Attorney Docket Number	018733-1317	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>MA</i>	A10	Seham, A. A. <i>et al.</i> , "Improving the Tumor Retention of Radioiodinated Antibody: Aryl Carbohydrate Adducts," <i>Cancer Research</i> (Suppl.) (February 1990) 50:783-788.	
<i>MC</i>	A11	Pawlak-Byczkowska, E. J. <i>et al.</i> , "Two New Monoclonal Antibodies, EPB-1 and EPB-2, Reactive with Human Lymphoma," <i>Cancer Research</i> (August 1989) 49:4568-4577.	
<i>MA</i>	A12	Wilbur, D. S. <i>et al.</i> , "Development of a Stable Radioiodinating Reagent to Label Monoclonal Antibodies for Radiotherapy of Cancer," <i>Journal of Nuclear Medicine</i> (1989) 30:216-226.	
<i>MA</i>	A13	Stein, R. <i>et al.</i> , "Murine Monoclonal Antibodies Raised Against Human Non-Small Cell Carcinoma of the Lung: Specificity and Tumor Targeting," <i>Cancer Research</i> (February 1990) 50:1330-1336.	
<i>MA</i>	A14	Stein, R. <i>et al.</i> , "Effects of Radiolabeling Monoclonal Antibodies with a Residualizing Iodine Radio!abel on the Accretion of Radioisotope in Tumors," <i>Cancer Research</i> (July 1995) 55:3132-3139.	
<i>MA</i>	A15	Govindan, S. V., <i>et al.</i> , "Thiolations, ^{99m} Tc Labelings, and Animal n Vivo Biodistributions of Divalent Monoclonal Antibody Fragments," <i>Bioconjugate Chem.</i> (1996) 7:290-297.	
<i>MA</i>	A16	Hansen, H. J. <i>et al.</i> , "Characterization of Second-Generation Monoclonal Antibodies Against Carcinoembryonic Antigen," <i>Cancer</i> (June 1993) 71(11):3478-3485.	
<i>MA</i>	A17	Devys <i>et al.</i> , "Comparative Targeting of Human Colon-Carcinoma Multicell Spheroids Using One- and Two-step (Bispecific Antibody) Techniques," <i>Chemical Abstracts</i> (1996) 125(23):883-891.	
<i>MA</i>	A18	Bianchi, C. P., <i>Chemical Abstracts, 1-Pharmacology</i> (1988) 1:404-405.	
<i>MA</i>	A19	Govindan <i>et al.</i> , "Labeling of Monoclonal Antibodies with Diethyltriaminepentaacetic Acid-Appended Radioiodinated Peptides Containing D-Amino Acids" <i>Bioconjugate Chemistry</i> (1999) 10:231-240	

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>3/3/05</i>
--------------------	--------------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/713,268
		Filing Date	November 17, 2003
		First Named Inventor	S. V. GOVINDAN
		Art Unit	4616 1639
		Examiner Name	To Be Assigned
Sheet 1 of 1	Attorney Docket Number	40923-0067 US5 (018733-1317)	

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>[Signature]</i>	1.	Lee, H. et al., "Development of a Kit-Form Analog of Metaiodobenzylguanidine", The Journal of Nuclear Medicine, vol. 27, pp. 256-267 (1986)	
<i>[Signature]</i>	2.	Stein, R., et al., "Improved Iodine Radiolabels for Monoclonal Antibody Therapy", Cancer Research, vol. 63, pp. 111-118 (2003).	
<i>[Signature]</i>	3.	Weadock, K.S., et al., "Evaluation of a Remote Radioiodination System for Radioimmunotherapy", The Journal of Nuclear Medicine, Vol. 31, No. 4, pp. 508-510 (1990)	
	4.		
	5.		
	6.		
	7.		
	8.		
	9.		
	10.		
	11.		
	12.		
	13.		
	14.		
	15.		
	16.		
	17.		
	18.		
	19.		
	20.		
	21.		
	22.		
	23.		
	24.		
	25.		
	26.		
	27.		
	28.		

Examiner Signature	<i>[Signature]</i>	Date Considered	3/2/05
--------------------	--------------------	-----------------	--------

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.